지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 55 - 61 (7page)
이용수
초록· 키워드
오류제보하기
Background/Aims: The clinical use of measuring infliximab (IFX) trough levels (TLs) and antibodies against IFX (ATIs) in patients with pediatric inflammatory bowel disease (IBD) remains unclear. We propose measuring these variables to create individual IFX treatment strategies for patients with pediatric IBD. Methods: This retrospective study was conducted in pediatric patients with IBD who received IFX from July 2009 to June 2014. Results: Samples were available from 39 patients with pediatric IBD. A significant difference was observed in IFX TLs in 16 patients who were in clinical remission (group A) after IFX therapy (median, 3.99 μg/ mL; interquartile range [IQR], 0.30 to 21.96) compared to 23 patients who had a poor response to treatment (group B) (median, 0.88 μg/mL; IQR, 0.00 to 6.80, p=0.002). In group B, 21 patients underwent empiric intensification of IFX treatment. After dose intensification, 17 patients had an improved response to treatment. Four patients still had no response to dose intensification. Therefore, these patients were switched to other biologics. Conclusions: Patients who had poor responses and subtherapeutic IFX TLs had an improved response to dose intensification. Patients who had ATIs were likely to continue to have no response after dose intensification. Therefore, tailoring individual IFX treatments based on IFX TLs, ATIs, and the clinical response should be considered.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Steenholdt C / 2014 / Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial / Gut 63:919~927
Afif W / 2010 / Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease / Am J Gastroenterol 105
Baert F / 2003 / Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease / N Engl J Med 348 : 601 ~ 608
Ben-Horin S / 2011 / Review article: loss of response to anti-TNF treatments in Crohn’s disease / Aliment Pharmacol Ther 33 : 987 ~ 995
Bosani M / 2009 / Biologic targeting in the treatment of inflammatory bowel diseases / Biologics 3 : 77 ~ 97
Afif W / 2010 / Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease / Am J Gastroenterol 105
Baert F / 2003 / Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease / N Engl J Med 348 : 601 ~ 608
Ben-Horin S / 2011 / Review article: loss of response to anti-TNF treatments in Crohn’s disease / Aliment Pharmacol Ther 33 : 987 ~ 995
Bosani M / 2009 / Biologic targeting in the treatment of inflammatory bowel diseases / Biologics 3 : 77 ~ 97
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Intestinal research
2021 .10
-
Short-Term Outcome of Infliximab Therapy in Pediatric Crohn’s Disease: A Single-Center Experience
Pediatric Gastroenterology, Hepatology & Nutrition
2017 .01
-
Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan
Pediatric Gastroenterology, Hepatology & Nutrition
2021 .01
-
Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
Gut and Liver
2019 .01
-
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Gut and Liver
2021 .01
-
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn’s Disease: A Systematic Review of Real-World Evidence Studies
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Gut and Liver
2021 .01
-
High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
Intestinal research
2018 .01
-
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
Yonsei Medical Journal
2020 .01
-
Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
Yonsei Medical Journal
2021 .01
-
Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
Intestinal research
2022 .01
-
Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
Journal of Yeungnam Medical Science
2021 .01
-
Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
Gut and Liver
2016 .01
-
Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
Gut and Liver
2024 .05
-
Effects of COVID-19 vaccines on patient-reported outcomes in patients with inflammatory bowel disease: a multicenter survey study in Korea
Intestinal research
2024 .07
-
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
Intestinal research
2021 .01
-
Ophthalmologic manifestations in patients with inflammatory bowel disease
Intestinal research
2017 .01
-
Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Gut and Liver
2020 .01
-
Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease
Gut and Liver
2019 .01
-
Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Intestinal research
2023 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0